FDA Details National Vaccine Plan - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Details National Vaccine Plan


Dr. Karen Midthun, director of FDA’s Center for Biologics Evaluation and Research, outlined the importance of the Department of Health and Human Services (HHS) National Vaccine Plan, in a FDA blog on March 11, 2014. Midthun points out how crucial vaccines are in protecting public health and discusses FDA’s role in ensuring a stable supply of safe vaccines.

According to Midthun, the National Vaccine Plan plans on developing new vaccines, enhancing the vaccine safety system, supporting enhanced communication regarding vaccine decision-making, ensuring a stable supply of vaccines, and increasing global prevention of disease through vaccination. The National Vaccine Program Office recently issued the State of the National Vaccine Plan, which details the government’s progress regarding the vaccine plan. Some of the accomplishments listed in the report include the establishment of a new generation of influenza vaccines, new production techniques, and advances in electronic health data. Other accomplishments include the establishment of Vaccines.gov and vaccine promotional materials.

The report states that the National Vaccine Plan will continue in the coming years with more research into new vaccines, extension of monitoring systems, and continued development of communication paths. The report can be found on the HHS website.

Source: FDA.gov

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here